The recent surge in interest for Hong Kong-listed 18A surgical robotics companies has seen TH MEDICAL-B (02697) make a spectacular debut. The stock opened 159.3% higher on its first trading day at HK$327.2 and continued to climb, reaching an intraday high of HK$384.0. By the morning close, it was trading at HK$375.2, up 197.3%. The company's Hong Kong public offering was oversubscribed by 1790.4 times, setting a new record for its sector. While the market focuses on short-term IPO gains, few have dug deeper. In the percutaneous puncture sector, which is just emerging from the lab, the product strategies of different companies represent fundamentally different businesses. Some bet on a single, lightweight product to quickly gain market share with cost-effectiveness. Others tie themselves to imaging giants to break through via distribution channels. TH MEDICAL has chosen a heavier but more fortified path: a full-stack integrated solution from puncture diagnosis to ablation therapy. It is currently the only domestic company with commercialized products for both mature puncture surgical robots and ablation surgical robots. This article will set aside short-term stock price fluctuations and financial figures to examine three product lines—the TH-S high-end series, TH-P grassroots series, and TH-X ablation platform—from the perspective of fundamental clinical pain points. Through comparison with peers, we will clarify three questions: Why is the "puncture + ablation integration" the ultimate path in this sector? Where does TH MEDICAL's product matrix truly excel compared to peers? How will this product moat ultimately translate into commercial certainty?
Understanding the Clinical Core: Two Major Pain Points in Percutaneous Surgery
To assess the value of a surgical robot, one must look beyond technical specs to whether it solves genuine "hard pain points" in clinical practice. The percutaneous puncture and ablation sector still faces two industry-wide challenges not fully addressed by traditional solutions.
The first pain point is the high reliance on physician skill for manual puncture, leading to hesitation and inaccuracy with high-risk lesions. Organs like the lungs and liver shift continuously with respiration, with lesion displacement per breath cycle reaching 1-2 cm. For sub-5mm micronodules, deep lesions over 10cm, or those adjacent to major vessels, even experienced interventional radiologists require repeated CT scans and needle adjustments. This prolongs procedure time, increases patient radiation exposure, and elevates the risk of complications like pneumothorax and bleeding with each puncture attempt. Clinical trial data from the prospectus is telling: traditional manual puncture had a first-pass success rate of only 15.0%, with an average of 1.42 needle adjustments per procedure and a complication rate of 13.33%. With robotic assistance, the first-pass success rate rose to 98.3%, average adjustments dropped to 0.02, and complication risks were nearly halved. Among the 19 domestically approved puncture robots in China, most only offer basic image-guided navigation, solving the "clear visualization" problem but failing to form a complete closed loop from planning to execution.
The second, more subtle but impactful pain point is the disconnect between puncture diagnostic and ablation therapeutic equipment, creating a natural break in the clinical workflow. The common industry model involves using one navigation system for puncture and then switching to a third-party microwave ablation device for treatment. This switch requires re-registration and re-tracking of respiratory motion, not only lengthening the procedure but also potentially causing incomplete ablation coverage due to respiratory drift, directly affecting tumor treatment efficacy. Globally, only TH MEDICAL's TH-X MW is an approved product that natively integrates puncture navigation, robotic arm positioning, respiratory tracking, and microwave energy output on a single platform—the core reason for its "world-first" designation by the National Medical Products Administration (NMPA). In essence, while most players are still running the "diagnostic half," TH MEDICAL has completed the full "diagnosis + treatment" marathon. This is not a difference in features but a generational gap.
A Three-Tier Product Matrix with Unmatched Coverage
TH MEDICAL's product strategy is clear: use high-end flagship models to set clinical benchmarks, compact models to penetrate grassroots markets, and integrated ablation products to build an exclusive moat, forming a three-tier structure that peers cannot easily replicate in the short term.
First, the TH-S series sets the benchmark in the high-end segment with unmatched certification speed. The four models in this series belong to the same registration unit but are certified and commercialized separately, a "multi-certificate strategy" that precisely targets the stratified needs of the domestic medical market. The most notable is the TH-S1, approved in May 2022, which was China's first percutaneous puncture robot to integrate intelligent image reconstruction, infrared binocular navigation, a six-degree-of-freedom robotic arm, and real-time respiratory tracking. Its value lies not just in selling equipment but in capturing benchmark clinical cases and establishing physician mindshare as a "technical calling card" for the brand.
Second, the TH-P series represents a unique strategic tool for the grassroots market. While almost all competitors crowd into the niche tertiary hospital market, they overlook the larger, more pressing needs of county-level healthcare—simply because they cannot develop compact products balancing performance and cost. TH MEDICAL's TH-P series achieves this through in-house development of a miniaturized robotic arm and domestic substitution of core components, significantly reducing the overall size and manufacturing cost while retaining key technologies like sub-millimeter navigation and respiratory tracking. This product expands the application of puncture surgical robots from provincial tertiary hospitals to prefectural hospitals, county hospitals, and specialized biopsy centers, unlocking a market several times larger than the current one.
Third, the TH-X series is the true exclusive moat, unmatched across the sector. If puncture robots are an area for competing on specs and price, integrated ablation surgical robots are TH MEDICAL's sole territory. The disruptive nature of the TH-X MW lies in redefining the percutaneous puncture ablation workflow: automatic lesion segmentation and planning of needle path and ablation zone pre-operatively; robotic guidance of the ablation needle with real-time respiratory tracking and dynamic adjustment of energy output intra-operatively; and immediate post-operative assessment of target coverage. The entire process requires no device switching or re-registration, truly achieving "one needle insertion, complete diagnosis + treatment." Compared to the industry's common patchwork solution of a "navigation platform + third-party ablation device," this natively integrated product holds a generational advantage in puncture accuracy, ablation efficacy, and procedural efficiency, justifying its "world-first" status.
Peer Comparison Highlights Full-Stack Advantage
Comparing major domestic and international players reveals three clear conclusions. First, TH MEDICAL leads by a wide margin in the number of approved products. Out of 21 approved puncture robots industry-wide, TH MEDICAL holds 5, 2.5 times more than the runner-up. Most companies are still at the "having a product" stage with only one Class III certificate, while TH MEDICAL has entered the "matrix" stage.
Second, it holds a monopoly in the ablation segment. No other domestic company currently has an approved integrated microwave ablation surgical robot. Competitors offering ablation must rely on navigation devices paired with third-party microwave units, making them essentially "puncture service providers" rather than "treatment solution providers."
Third, its price coverage is the most complete. While others can only compete for tertiary hospital budgets, TH MEDICAL can secure benchmark orders from top hospitals with the TH-S series while capturing incremental demand from grassroots markets with the TH-P series, giving it far greater anti-cyclical strength and long-term growth potential than single-product players.
Regulatory Speed as a Core Competency
In the medical device industry, regulatory approval capability is core to productivity. Obtaining a Class III medical device registration certificate typically takes 3-5 years from R&D to final approval, with costs running into tens of millions—a process not easily accelerated by capital alone. TH MEDICAL's approval cadence is exceptional within the sector, averaging at least two new products or new indications per year. This efficiency stems from deep regulatory understanding, solid clinical data, and a complete R&D-registration system. More crucially, the "domestic-first + world-first" dual certifications carry significant weight, strongly influencing hospital procurement decisions and facilitating future product approvals. For followers starting R&D now, a 3-year gap to certification is likely, giving TH MEDICAL a golden window to capture hospital channels, accumulate clinical data, and build physician mindshare.
From Product Matrix to Commercialization
The value of a product matrix may not appear immediately in financial reports but determines the commercial ceiling and growth resilience over the next 3-5 years.
First, the per-hospital value ceiling is higher, with a more stable consumables loop. While a single-product player sells one device per hospital with limited follow-on consumables, TH MEDICAL's model allows a hospital to purchase both puncture and ablation robots for multi-departmental use (respiratory, thoracic, hepatobiliary, interventional), naturally yielding higher output per site. More importantly, consumables like specialized puncture and ablation needles represent recurring revenue. As installed base grows, consumables' contribution to revenue rises, improving profit quality—a trend already beginning in 2024.
Second, full price-band coverage allows precise capture of policy tailwinds. Following the national unified fee framework issued in early 2026, hospitals can finally calculate ROI for device purchases. However, payment capabilities vary drastically: tertiary hospitals can afford high-end flagships, while county hospitals need cost-effective models. TH MEDICAL's three-tier matrix aligns with these different budget ranges, enabling it to benefit from both tertiary hospital upgrades and grassroots adoption waves simultaneously.
Third, forward-looking pipelines and overseas expansion open long-term growth potential. Beyond current commercial products, the company has two advanced pipelines: the TH-X Cryo cryoablation robot and an ex-vivo organ preservation and assessment system. The organ preservation line, in particular, addresses a nearly blank domestic market and could become a completely independent second growth curve. For overseas markets, CE certification for the TH-S1 has been applied for, with approval expected in Q4 2026. Leveraging its Australian background and Hengqin location, TH MEDICAL has inherent internationalization advantages, and its products possess globally leading technical competitiveness, making overseas expansion a tangible near-term opportunity rather than a distant story.
A Balanced View of Risks
No investment is without risk, and hard-tech companies come with specific uncertainties. First, the pace of commercial conversion is uncertain. Hospital procurement cycles for large equipment are long, with trials to formal tenders potentially taking 1-2 years, meaning sales ramp-up may be slower than market expectations. Second, industry competition is intensifying, with players like United Imaging and Tuodao entering the field, raising the objective risk of price and channel wars. Third, the implementation pace of medical insurance fee schedules varies by region. While a national framework exists, local execution differences may affect procurement willingness in some areas. These are challenges common to all medical device companies in the early commercialization phase, not unique to TH MEDICAL. The key judgment is not whether risks exist, but whether the company possesses sufficient moats to navigate them.
Ultimately, the true value proposition for TH MEDICAL lies not in its current revenue but in its multiple Class III certificates, dual "first" technology endorsements, full-stack "puncture + ablation" closed loop, and complete product portfolio covering markets from tertiary to county levels. These are advantages built through years of clinical and regulatory grind, not easily replicated by spending on marketing, and represent barriers peers cannot quickly overcome. As policy tailwinds materialize, trial installations convert to formal orders, and consumables recurring revenue gains momentum, what the market sees as "small revenue" today could transform into a compounding growth story. The narrative for puncture surgical robots is just beginning, and the player holding the strongest hand is often the one that walks the steadiest and longest path.